D-Pharm in deal to co-develop its late-stage stroke drug in China
This article was originally published in Scrip
Executive Summary
The Israeli firm D-Pharm has signed a licensing, co-development and supply deal with Wanbang Biopharmaceuticals, a subsidiary of Fosun Pharmaceutical Group, whereby the two firms will jointly develop D-Pharm's investigational stroke treatment, DP-b99, in China.